Physician profile
Gary A Thomas
NPI 1831125731
$2,671.70
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $198 · 2020: $187 · 2021: $438 · 2022: $914 · 2023: $934.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $934.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $934.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $643.85 | 2019-2023 | Rinvoq, Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $328.50 | 2019-2023 | Xifaxan, Plenvu |
| Janssen Biotech, INC. | $299.39 | 2020-2023 | Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $262.71 | 2022-2023 | Entyvio, Gattex |
| Braintree Laboratories, INC. | $229.16 | 2020-2022 | |
| Pfizer INC. | $220.83 | 2019-2023 | |
| Organon LLC | $139.94 | 2023 | Hadlima, Renflexis |
| Regeneron Healthcare Solutions, INC. | $71.47 | 2019-2023 | Dupixent |
| Genzyme Corporation | $67.08 | 2022-2023 | |
| Celgene Corporation | $65.26 | 2021-2023 | Zeposia |
| Amgen INC. | $59.27 | 2022-2023 | Amjevita, Avsola |
| Medtronic, INC. | $53.38 | 2023 | Gi Genius, Interstim |
| Cook Medical LLC | $48.03 | 2020-2021 | |
| Qol Medical, LLC | $40.76 | 2019-2022 | |
| Daiichi Sankyo INC. | $26.80 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $26.23 | 2019-2021 | |
| Allergan, INC. | $24.14 | 2020 | |
| Merck Sharp & Dohme LLC | $14.95 | 2023 | Dificid |
| Nestle Healthcare Nutrition INC. | $14.20 | 2023 | |
| Intercept Pharmaceuticals, INC. | $12.15 | 2019 | |
| Novo Nordisk INC | $11.96 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.64 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$7,005.35 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.